VTAK

VTAK Acquires 20% Interest in Creatd’s Subsidiary Fly Flyte, Inc.

Feb 17, 2026

Strategic Partnership: Creatd expanded Fly Flyte’s investor network by adding NYSE-listed VTAK as an investor in its subsidiary. Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions. Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. New York, NY, Feb. 17, 2026, - PRISM MediaWire (Press Release Service - Press Release Distribution) -...

Catheter Precision, Inc. Receives CE Mark for LockeT

May 27, 2025

Opens Multi-Billion Market Opportunity for the Company First Order for 100 Units Received FORT MILL, S.C., May 27, 2025 - PRISM MediaWire - Catheter Precision, Inc. (NYSE American: VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has received CE Mark approval for LockeT, the latest advanced vascular closure device. Receipt of the CE Mark indicates compliance with European Union (EU)...

Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy

Feb 10, 2025

BRIDGEWATER, NJ, February 10, 2025 - PRISM MediaWire - Catheter Precision Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a U.S.-based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced its engagement with PCG Advisory, a leading investor relations, strategic communications, and digital strategies firm, to enhance investor outreach and communication efforts. By partnering with PCG...

NEWSROOM

VTAK Acquires 20% Interest in Creatd’s Subsidiary Fly Flyte, Inc.

Catheter Precision, Inc. Receives CE Mark for LockeT

Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy

Contact Us